In the realm of quality assurance (QA), it’s vital that standard operating procedures (SOPs) are crafted in a way that accurately and specifically reflects the control measures, tasks, and processes that the organization can directly influence and manage. Here are several reasons why it is not advisable to include processes in SOPs that you have no control over, such as country-specific regulations for Real-World Evidence (RWE) studies:
[1] Inaccuracy and Inconsistency: Country-specific regulations can vary significantly and may change over time. The organization has no control over these changes and thus cannot guarantee that their SOPs will stay up-to-date with the current regulations in each country.
[2] Potential for Non-Compliance: If the SOP includes processes dictated by external regulations that subsequently change, the company might unknowingly be in non-compliance. This could lead to regulatory consequences, including fines or other penalties.
[3] Confusion: Inclusion of country-specific regulations in the SOPs can cause confusion among the staff who are required to follow these procedures. If an SOP describes a procedure that is not applicable or is different in their specific context, this could lead to errors, misunderstandings, or non-compliance.
[4] SOP Management Complexity: SOPs should be as concise, clear, and easy to manage as possible. By including country-specific regulations, the SOPs become more complex and harder to maintain, which increases the risk of errors and decreases efficiency.
Instead of including country-specific regulations in SOPs, a better approach would be to make SOPs generic enough to accommodate various situations, while ensuring compliance with overarching international or regional regulations. Furthermore, local teams should be trained and have access to resources that detail the country-specific regulations applicable to them. They could also have local operating procedures or instructions that explain how the SOP should be implemented in light of these regulations.
Finally, there should be a process in place to ensure that the organization is constantly up-to-date with any changes in country-specific regulations and can adjust its procedures accordingly. This might involve dedicated personnel or teams, use of regulatory consultancy services, or subscription to regulatory update feeds. These processes would lie outside the SOPs, but would be critical to maintaining regulatory compliance.
Share this story...
Real World Evidence (RWE) 101 – Parkinson’s Disease
RWE 101 - Parkinson’s Disease Real-world evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a treatment derived from analysis of real-world data [...]
Real World Evidence (RWE) 101 – Benefits of RWE in the Context of Rare Diseases
RWE 101 - Benefits of RWE in the Context of Rare Diseases Real-world evidence (RWE) refers to information on health care that comes from real-world settings, such as electronic [...]
Real World Evidence (RWE) 101 – Disease Prevalence vs Incidence
RWE 101 - Disease Prevalence vs Incidence Real-world evidence (RWE), derived from real-world data (RWD), allows us to gain insights into disease prevalence and incidence outside of controlled clinical [...]
Real World Evidence (RWE) 101 – Principles for Ensuring that Research Results are Reliable, Valid, and Objective
RWE 101 - Principles for Ensuring that Research Results are Reliable, Valid, and Objective Ensuring that research results are reliable, valid, and objective requires careful planning, execution, and evaluation. [...]
Real World Evidence (RWE) 101 – Why Should Non-Interventional Studies NOT be Promotional?
RWE 101 - Why Should Non-Interventional Studies NOT be Promotional? Non-interventional studies (NIS) are designed to observe and analyze data from real-world clinical settings without intervening or manipulating any [...]
Real World Evidence (RWE) 101 – Seeding Studies
RWE 101 - Seeding Studies Seeding studies, in the context of real-world evidence (RWE), refer to studies that were conducted by pharmaceutical or medical device companies after a product's [...]







